CRISPR-Based Therapy for Hereditary Angioedema

遗传性血管水肿 清脆的 医学 计算生物学 遗传学 生物 皮肤病科 基因
作者
Danny M. Cohn,Padmalal Gurugama,Markus Magerl,Constance H. Katelaris,D. Launay,Laurence Bouillet,Remy S. Petersen,Karen Lindsay,Emel Aygören‐Pürsün,David Maag,James S. Butler,Mrinal Y. Shah,Adele Golden,Yuanxin Xu,Ahmed M. Abdelhady,David Lebwohl,Hilary Longhurst
出处
期刊:The New England Journal of Medicine [New England Journal of Medicine]
标识
DOI:10.1056/nejmoa2405734
摘要

BackgroundHereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.MethodsIn this phase 2 portion of a phase 1–2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo. The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16. Secondary end points included safety, pharmacokinetics, and pharmacodynamics (i.e., the change from baseline in total plasma kallikrein protein level); exploratory end points included patient-reported outcomes.ResultsOf the 27 patients who underwent randomization, 10 received 25 mg of NTLA-2002, 11 received 50 mg, and 6 received placebo. From week 1 through week 16, the estimated mean monthly attack rate was 0.70 (95% confidence interval [CI], 0.25 to 1.98) with 25 mg of NTLA-2002, 0.65 (95% CI, 0.24 to 1.76) with 50 mg, and 2.82 (95% CI, 0.80 to 9.89) with placebo; the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was −75% with 25 mg and −77% with 50 mg. Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16. The most common adverse events among patients who received NTLA-2002 were headache, fatigue, and nasopharyngitis. The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was −55% with 25 mg and −86% with 50 mg; levels remained unchanged with placebo.ConclusionsNTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830; EudraCT number, 2021-001693-33.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
谢谢发布了新的文献求助10
刚刚
细心沛山发布了新的文献求助30
2秒前
2秒前
科研通AI2S应助年轻的孤丹采纳,获得10
5秒前
6秒前
刘家骏发布了新的文献求助10
6秒前
852应助小林采纳,获得10
7秒前
科研牛马完成签到,获得积分10
9秒前
alan发布了新的文献求助10
10秒前
Yippee发布了新的文献求助10
10秒前
10秒前
11秒前
13秒前
哈哈嘿完成签到,获得积分10
15秒前
李小怂完成签到,获得积分20
15秒前
铎铎铎完成签到 ,获得积分10
16秒前
初一发布了新的文献求助10
17秒前
云瑾应助kkk采纳,获得10
18秒前
kk发布了新的文献求助10
19秒前
迪鸣完成签到,获得积分10
19秒前
zhido完成签到,获得积分10
19秒前
情怀应助幻天游采纳,获得10
19秒前
领导范儿应助danti采纳,获得10
20秒前
胡萝卜z发布了新的文献求助10
20秒前
朱大大666发布了新的文献求助10
22秒前
22秒前
23秒前
23秒前
斯文败类应助科研通管家采纳,获得10
23秒前
23秒前
薰硝壤应助科研通管家采纳,获得50
24秒前
彭于晏应助科研通管家采纳,获得10
24秒前
yufanhui应助科研通管家采纳,获得10
24秒前
天天快乐应助科研通管家采纳,获得10
24秒前
隐形曼青应助科研通管家采纳,获得10
24秒前
852应助李小怂采纳,获得10
24秒前
科研通AI2S应助科研通管家采纳,获得10
25秒前
英姑应助科研通管家采纳,获得10
25秒前
小蘑菇应助科研通管家采纳,获得10
25秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3055112
求助须知:如何正确求助?哪些是违规求助? 2711905
关于积分的说明 7428965
捐赠科研通 2356735
什么是DOI,文献DOI怎么找? 1248250
科研通“疑难数据库(出版商)”最低求助积分说明 606641
版权声明 596083